The development of targeted therapies with ALK inhibitors has shown positive outcomes in many tumor types, including other sarcomas such as inflammatory myofibroblastic tumors, where ALK inhibitors have shown benefits [23,24,25,26]. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.